The VisionGate® management team has considerable prior-company experience in the creation of cutting-edge technologies in both pharmaceuticals and diagnostics including late stage development, commercial new product planning and new product launch:
Alan C. Nelson, PhD – Founder, Chairman & CEO
Dr. Nelson, is founder, chairman and CEO of VisionGate. He is a physicist, bioengineer and entrepreneur who developed the world’s first and only automated screening test to detect cervical cancer, marketed today as FocalPoint by Becton Dickinson. He is former Executive Director of Arizona State University’s (ASU) Biodesign Institute and has held faculty positions at ASU, University of Washington, MIT and Harvard. Dr. Nelson holds more than 100 US patents and has more than 100 peer-reviewed publications in the field of biomedical imaging.
Scarlett Spring, MBA – President and Chief Commercial Officer
As president and chief commercial officer of VisionGate, Ms. Spring leads the day-to-day operations and commercialization planning. Ms. Spring’s experience ranges from executive leadership in a top 10 pharmaceutical company to chief operating officer at a nationally ranked public-private partnership to an innovative start-up. She is heavily involved in Phoenix area leadership as a board member of RepublicBankAZ, Pinnacle Transplant Technologies, AZ Tech Council and is a member of Charter 100. She was recently named one of Arizona’s Top Business Leaders and one of Arizona’s 50 Most Influential Women in Arizona Business Magazine.
Javier Zulueta, MD – Chief Medical Officer
Dr. Javier Zulueta is a world-renowned pulmonologist, professor and 16-year Director of Pulmonary Service at the University Clinic of Navarra, the teaching hospital of Spain’s University of Navarra School of Medicine. Dr. Zulueta led the longest ongoing lung cancer screening trial in Europe. The study is part of the International Early Lung Cancer Action Program (I-ELCAP) consortium, of which he has been the Principal Investigator since its inception in 2000. He has authored more than 100 publications in peer-reviewed journals and has been an invited lecturer at more than 100 international conferences.
Michael G. Meyer, MS– Chief Technology Officer
As CTO, Mr. Meyer manages efforts among the various technical groups and provides final technical arbitration. He also supervises development of the Cell-CT™ platform and training of algorithms to compute VisionGate test results as well as the development of technical strategies to validate them. He was previously a research scientist for TriPath Imaging, Inc. (formerly NeoPath), where he supervised a variety of efforts to develop algorithms to detect rarely occurring cervical neoplasms and their precursors on Pap smear slides. Prior to TriPath, he was employed at IBM in Rochester, MN.
Jon W. Hayenga, MS – Vice President, Advanced Product Development
Mr. Hayenga has 30 years of product development experience, 22 of it in FDA-regulated industry. He has held senior engineering and management roles in previous start-up biomedical technology companies, including NeoPath, where he delivered emerging complex technology products. Before joining VisionGate, Mr. Hayenga was director of engineering at Micronics where he developed patented technologies utilizing instrumentation and micro-fluidics solutions for the biotech industry. He holds more than 30 patents and contributes at the theoretical level as well as the applied level.
Stephen Phillips, BA/BS – Vice President, Quality Systems
Stephen Phillips is head of quality and oversees VisionGate’s quality systems. Mr. Phillips has 30 years of broad product development experience ushering new products through the quality, regulatory pathway, including diagnostic and therapeutic medical devices. He has held senior engineering and management roles in established as well as start-up biomedical technology companies. Before joining VisionGate, Mr. Phillips worked at Varian’s Calypso Medical division where he developed patented technologies for treating cancer.